2024-513676-18-00招募中3 期
A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)
Eidos Therapeutics Inc.29 个研究点 分布在 7 个国家目标入组 92 人开始时间: 2025年10月22日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 92
- 试验地点
- 29
- 主要终点
- Proportion of participants with: treatment-emergent AEs and SAEs, AEs leading to treatment discontinuation, abnormal physical examination findings of clinical relevance, abnormal vital signs of clinical relevance, abnormal ECG parameters ofclinical relevance, changes in clinical safety laboratory parameters of potential concern
研究概览
简要总结
To evaluate the long-term safety and tolerability of acoramidis in participants with newly diagnosed ATTR-CM
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Participants must have completed the AG10-501 study (ACT-EARLY study) within the past 60 calendar days with a diagnosis of ATTR-CM (based on the AG10-501 protocol definition of ATTR-CM).
- •Participant must be willing and able to give signed informed consent for participation in the study. Informed consent must be obtained prior to initiation of study procedures.
- •Agree to the use of highly effective contraception: a. FEMALE: WOCBP (defined as all women physiologically capable of becoming pregnant) who engage in heterosexual intercourse must agree to use a highly effective method of contraception from Day 1 and continuing for 30 calendar days after the last dose of study drug. (see Section 8.3.6). b. MALE: A male participant who has not had a vasectomy and is sexually active with a female of childbearing potential must agree to use a double-barrier method of birth control during the study and continue for 30 calendar days after the last dose of study drug. Males must agree to refrain from sperm donation for a minimum of 30 calendar days post the last dose of the study drug.
排除标准
- •Participants who completed the AG10-501 study with a diagnosis of ATTR-PN only or who permanently discontinued IMP prior to diagnosis of ATTR-CM in AG10-
- •In the judgment of the Investigator or Medical Monitor, has any clinically relevant ongoing medical condition or laboratory abnormality or other condition that might jeopardize the participant’s safety, increase the participant’s risk from participation, interfere with the study, or confound study results.
- •Participation in another investigational clinical trial. Participation in observational and/or registry studies must be discussed with the Medical Monitor.
- •Major surgery planned during the next 6 months. For participants who may have required major surgery during their participation in the AG10-501 study and the decision by the Investigator at that time was to continue the participant in the AG10-501 study, that participant may still qualify for Study AG10-504 provided study participation does not interfere with the surgical care plan and vice versa.
- •History of light-chain amyloidosis (AL) or another non-TTR amyloid subtype (eg, ApoA 1, gelsolin).
- •History of a monoclonal paraprotein or abnormal light chains in serum or urine (ie, MGUS) in which AL has not been ruled out.
- •Stage IV or V chronic kidney disease (corresponding to an eGFR ≤ 29 mL/min/1.73 m2), or undergoing renal dialysis, or recipient of a kidney transplant.
- •Active malignancy, except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix that has been successfully treated. In the event a participant developed a low-grade and treatable malignancy in the AG10-501 study (eg, low-grade, localized prostate cancer) and the decision by the Investigator at that time was to continue the participant in the AG10-501 study, that participant may still qualify for Study AG10504 after documentation with the Medical Monitor.
- •History of any organ transplant (with the exception of corneal transplant).
- •Known hypersensitivity to acoramidis or any of the excipients within the study drug.
- •Treatment for ATTR-CM with any ATTR-oriented on- or off-label or OTC product.
- •Female participants who are pregnant or breastfeeding. A negative urine pregnancy test on Day 1 prior to dosing is required for WOCBP. A positive urine dipstick pregnancy test will need to be confirmed with a serum test and participants cannot commence AG10-504 study unless the serum test results return negative.
结局指标
主要结局
Proportion of participants with: treatment-emergent AEs and SAEs, AEs leading to treatment discontinuation, abnormal physical examination findings of clinical relevance, abnormal vital signs of clinical relevance, abnormal ECG parameters ofclinical relevance, changes in clinical safety laboratory parameters of potential concern
Proportion of participants with: treatment-emergent AEs and SAEs, AEs leading to treatment discontinuation, abnormal physical examination findings of clinical relevance, abnormal vital signs of clinical relevance, abnormal ECG parameters ofclinical relevance, changes in clinical safety laboratory parameters of potential concern
次要结局
- 1. All-cause mortality and cardiovascular mortality
- 2. Cardiovascular-related hospitalization
- 3. Participants with: • Any HF event: O-HF and/or UV-HF and/or H-HF • UV-HF and/or H-HF • O-HF • UV-HF • H-HF • NOHF
- 4. Development of symptomatic ATTR-CM as defined by the investigator
- 5. New arrhythmia and cardiac conduction complications (not otherwise attributable to a non-amyloid cause) as defined by: • New onset of atrial fibrillation or atrial flutter and/or • Sustained ventricular tachycardia or sudden cardiac death and/or • New onset 1st or 2nd degree atrioventricular block and/or • Conduction disease requiring temporary transvenous or permanent pacemaker implantation
- 6. New diagnosis of or therapeutic surgery (not otherwise attributable to a non-amyloid cause) for: • Carpal tunnel syndrome and/or • Brachial biceps tendon rupture or Achilles tendon rupture and/or • Lumbar spinal stenosis and/or • Hip and knee osteoarthritis and/or • Trigger finger and/or • Rotator cuff osteoarthritis
- 7. Change from baseline in: o Echocardiographic and strain parameters that estimate myocardial structure and function o NT-proBNP and hsTnI
研究者
Adam Castano
Scientific
Eidos Therapeutics Inc.
研究点 (29)
Loading locations...
相似试验
招募中
3 期
A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammatory myopathy.2022-502851-79-00Argenx80
招募中
2 期
A trial to learn how safe AZD3632 is, how well it works, and how it moves throughout the body over time in adults with acute leukemia and myelodysplastic syndrome with HOX gene overexpression2025-521299-76-00AstraZeneca AB1
招募中
3 期
ELEVATE UC OLE: An Open-Label Extension Study for Treatment of Moderately to Severely Active Ulcerative ColitisUlcerative Colitis2024-515156-21-00Arena Pharmaceuticals Inc.298
招募中
2 期
A study to assess the long-term safety and efficacy of a subcutaneous
formulation of efgartigimod in adults with chronic inflammatory
demyelinating polyneuropathy (an autoimmune disorder that affects the
peripheral nerves)Chronic Inflammatory Demyelinating Polyneuropathy2023-507885-21-00Argenx88
已完成
3 期
A study to learn if lacosamide is safe to take over a long period of time in children with epilepsyEpilepsy2022-502639-21-00UCB Biopharma19